Phase III Study and Meta-Analysis Results with Bevacizumab and First-Line Chemotherapy for Metastatic Breast Cancer (mBC)
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVES

• Compare and contrast the efficacy and safety of bevacizumab-containing therapy by breast cancer subtype and patient age.
• Counsel patients with triple-negative breast cancer (TNBC) about the benefits and risks of first-line chemotherapy in combination with bevacizumab.
• Cite the rates of pathologic complete response and serious adverse events when bevacizumab is combined with neoadjuvant epirubicin and cyclophosphamide or doxorubicin for patients with untreated HER2-negative early breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

No real or apparent conflicts of interest to disclose.

William J Gradishar, MD
Director, Breast Medical Oncology
Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: January 2011
Expiration date: January 2012
Click here for papers on the modest benefit observed in patients with TNBC receiving chemotherapy and either bevacizumab or cetuximab.

Click here for papers on a Phase IB trial combining the PARP inhibitor iniparib and irinotecan in metastatic breast cancer, a study on the in vitro effects of iniparib on a TNBC cell line and a fascinating report suggesting that epigenetic promoter methylation of BRCA genes may correlate with BRCAness and response to PARP inhibitors.

I love my job and feel profoundly privileged to have the opportunity to listen to the great minds in the field and was reminded of this during an annual December visit to the Lone Star State where, as usual, I never made it to the River Walk but sure heard a lot of interesting stuff. One of the highlights was my first ever interview with Alan Ashworth, director of the Breakthrough Breast Cancer Research Centre in London and one of the emerging research giants in the field. This conversation for our audio series was an amazing lesson in the biology and treatment implications of tumor DNA repair and occurred hours after he received a major award from the meeting and gave a brilliant and highly understandable lecture on this subject. This issue of our series profiles a number of San Antonio papers related to management of TNBC (see above links), but the biology and therapeutics discussed by Professor Ashworth seem a lot more encouraging for the future of this disease subset. Below find a few choice highlights of the interview.

**Dr Love: What do we know about BRCA mutations and DNA repair?**

**Prof Ashworth:** The BRCA1 and BRCA2 genes are involved in a repair pathway for double-strand DNA breaks that occur very close to each other. An elaborate mechanism called homologous recombination fixes some of these double-strand breaks, and BRCA2 and BRCA1 are critical for homologous recombination.
Where does PARP fit in?
PARP is a very active enzyme involved in the repair of single-strand breaks in DNA or modified bases. It binds to DNA damage and adds multiple sugar molecules to the DNA that act as a beacon to recruit other components of DNA repair.

What about PARP inhibitors?
The PARP enzyme was discovered in the early 1960s, and PARP inhibitors have been around for 20-odd years. Most of the early ones were not very potent or specific. Recently a number of more specific and potent PARP inhibitors have been developed.

How does this tie in to synthetic lethality?
Synthetic lethality is about exploiting the genetic defects in tumors and involves an underlying linkage between two biochemical pathways in which a defect in one pathway (eg, homologous recombination) doesn’t have any ostensible effects, and then a separate defect in another (eg, DNA base excision repair) has no ostensible effects but when you put them together, you get a combination or synthesis of lethalities.

What are your thoughts on the concept of BRCAness — particularly as it relates to triple-negative breast cancer?
BRCAness is when you have a defect in the pathway of homologous recombination not caused by mutations in BRCA1 or BRCA2. Triple-negative
tumors look like the tumors that arise in BRCA1 mutation carriers, and that’s part of the reason we developed this concept. One can imagine assays for BRCAness that involve measuring DNA repair processes in tumors, and this could become the ultimate gold standard to determine whether a patient might respond to a PARP inhibitor.

**It sounds like we aren’t there yet.**
We’re close. The recently published work of Nick Turner in my lab focuses on RAD51, which switches on in response to DNA damage as a marker of homologous recombination. Patients with tumors that don’t have RAD51 tend to resemble the phenotypes of BRCAness and look more like triple-negative cancers. So if we can prove this in a prospective trial, we believe it can be used in patient selection for PARP inhibitors.

**What about emerging work on assays for PARP?**
There is a school of thought that PARP levels might correlate with response to PARP inhibitors. It’s kind of a traditional view of a target and drug that go together. I believe that’s missing the point a bit it terms of what synthetic lethality is. All the data so far are either preliminary or unpublished, and we’d like to see proper studies to establish whether PARP levels are related to response to treatment.

**Do you think that’s what eventually will be demonstrated?**
No, I don’t think so. But that’s my guess. I have no proof of that.

After listening intently to this master professor for more than 60 minutes, together we joined a stellar faculty at a symposium our CME group hosted that night on, what else, TNBC. During that meeting, Prof Ashworth further elaborated on these topics and we explored other molecular and clinical developments in this patient subset that is about as common as HER2-positive disease ([click here](#) to see the symposium slides). By the end my head was spinning but my spirits were lifted because although SABCS 2010
might not have altered very much in terms of practical management of TNBC, major and exciting changes seem to be just around the corner.

Next up on this San Antonio highlight series: Seven years after another memorable interview — when Soon Paik first told us about the NSABP data on Onco
type DX® — more data and the announcement of a new node-positive trial on the use of genomic assays in the selection of patients for adjuvant chemotherapy.

Neil Love, MD
Research To Practice
Miami, Florida
Phase III Study and Meta-Analysis Results with Bevacizumab and First-Line Chemotherapy for Metastatic Breast Cancer (mBC)

Presentations discussed in this issue

Pritchard KI et al. Final overall survival results, including analysis of patients with triple-negative disease and aged ≥70 years, from the Athena study evaluating first-line bevacizumab-containing therapy for locally recurrent (LR)/metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2010; Abstract P2-16-06.

O'Shaughnessy J et al. Meta-analysis of patients with triple-negative disease from three randomized trials of bevacizumab and first-line chemotherapy as treatment for metastatic breast cancer. San Antonio Breast Cancer Symposium 2010; Abstract P6-12-03.


Slides from presentations at SABCS 2010 and transcribed comments from recent interviews with Harold J Burstein, MD, PhD (12/22/10) and William J Gradishar, MD (1/4/11)

Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the Athena Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent (LR)/ Metastatic Breast Cancer (mBC)

Pritchard KI et al. Proc SABCS 2010; Abstract P2-16-06.
Study Design

Accrual: 2,264 (Closed)

Eligibility

- HER2-negative LR/mBC
- No prior chemotherapy for LR/mBC; no concomitant endocrine therapy
- No uncontrolled hypertension
- No increased risk of hemorrhage
- No surgery in previous 28 days

Bevacizumab + chemotherapy*, until disease progression

* Taxane-based or alternative, excluding anthracycline, if taxane is not considered standard of care

Primary objective: Assess safety of bevacizumab in combination with chemotherapy as first-line treatment for LR/mBC in routine oncology practice.

Secondary objectives: Time-to-progression (TTP) and overall survival (OS).

Pritchard KI et al. Proc SABCS 2010;Abstract P2-16-06.

Chemotherapy Combination Partners

<table>
<thead>
<tr>
<th>Chemotherapy</th>
<th>Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paclitaxel monotherapy</td>
<td>34</td>
</tr>
<tr>
<td>Docetaxel monotherapy</td>
<td>33</td>
</tr>
<tr>
<td>Taxane combination</td>
<td>11</td>
</tr>
<tr>
<td>Capecitabine monotherapy</td>
<td>5</td>
</tr>
<tr>
<td>Vinorelbine monotherapy</td>
<td>3</td>
</tr>
<tr>
<td>Non-taxane combination</td>
<td>2</td>
</tr>
<tr>
<td>Other monotherapy</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Sequential chemotherapy*</td>
<td>12</td>
</tr>
</tbody>
</table>

*Switching chemotherapy regimen before disease progression while continuing bevacizumab.

Pritchard KI et al. Proc SABCS 2010;Abstract P2-16-06.
### Subgroup Analyses of TTP and OS

<table>
<thead>
<tr>
<th>Subgroup</th>
<th># of pts</th>
<th>Median TTP (months)</th>
<th>Median OS (months)</th>
<th>1-year OS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>2264</td>
<td>9.7</td>
<td>25.2</td>
<td>72.7</td>
</tr>
<tr>
<td>TNBC</td>
<td>585</td>
<td>7.2</td>
<td>18.3</td>
<td>59.8</td>
</tr>
<tr>
<td>Non-TNBC</td>
<td>1616</td>
<td>10.6</td>
<td>27.3</td>
<td>77.3</td>
</tr>
<tr>
<td>Age ≥ 70</td>
<td>176</td>
<td>10.4</td>
<td>20.5</td>
<td>68.2</td>
</tr>
<tr>
<td>Age &lt; 70</td>
<td>2088</td>
<td>9.6</td>
<td>25.5</td>
<td>73.0</td>
</tr>
<tr>
<td>Weekly paclitaxel monotherapy</td>
<td>325</td>
<td>10.6</td>
<td>24.5</td>
<td>71.7</td>
</tr>
<tr>
<td>3-weekly paclitaxel monotherapy</td>
<td>285</td>
<td>9.1</td>
<td>24.7</td>
<td>67.4</td>
</tr>
<tr>
<td>Docetaxel monotherapy</td>
<td>741</td>
<td>9.1</td>
<td>25.5</td>
<td>76.0</td>
</tr>
</tbody>
</table>

TNBC = triple-negative breast cancer

Pritchard KI et al. Proc SABCS 2010;Abstract P2-16-06.

### Conclusions

- Mature results from the ATHENA study conducted with patients treated in routine oncology practice demonstrate median OS of 25.2 months.
  - Consistent with reported Phase III trials evaluating first-line chemotherapy plus bevacizumab (25.2 to 30.2 months)
- No new safety signals emerged with longer follow-up and 21% of patients remained on bevacizumab > 1yr (data not shown).
- Subgroup analyses suggest that bevacizumab-containing therapy is an effective treatment in important patient populations with limited available treatment options.
  - TNBC: median OS = 18.3 months
  - Aged ≥ 70: median OS = 20.5 months

Pritchard KI et al. Proc SABCS 2010;Abstract P2-16-06.
Meta-Analysis of Patients with Triple-Negative Disease from Three Randomized Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Metastatic Breast Cancer

O’Shaughnessy J et al.
Proc SABCS 2010;Abstract P6-12-03.

Background

- Phase III trials have demonstrated improved progression-free survival (PFS) with the addition of bevacizumab (Bev) to first-line chemotherapy in a subset of patients with TNBC.
  - PFS RIBBON-1: 6.1 months (Bev + capecitabine arm)
  - PFS E2100: 10.6 months (Bev + weekly paclitaxel arm)
- A meta-analysis of individual patient data from the three randomized trials confirmed increased PFS but found no difference in OS (J Clin Oncol 2010;28:1005).
- **Current Study Goals:** Using individual patient data, assess the pooled efficacy and safety results for the subpopulation of patients with TNBC treated in three Phase III trials of first-line chemotherapy plus Bev.

O’Shaughnessy J et al. Proc SABCS 2010;Abstract P6-12-03.
## Efficacy Summary
**(n = 621 Patients with TNBC)**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Bevacizumab + chemotherapy (n = 363)</th>
<th>Chemotherapy alone (n = 258)</th>
<th>Hazard ratio*</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective response</td>
<td>42%</td>
<td>23%</td>
<td>—</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Progression-free survival (PFS), events</td>
<td>71%</td>
<td>75%</td>
<td>0.649</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Median PFS</td>
<td>8.1 months</td>
<td>5.4 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall survival (OS), events</td>
<td>68%</td>
<td>67%</td>
<td>0.959</td>
<td>0.6732</td>
</tr>
<tr>
<td>Median OS</td>
<td>18.9 months</td>
<td>17.5 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One-year OS rate</td>
<td>70.9%</td>
<td>64.8%</td>
<td>—</td>
<td>0.1140</td>
</tr>
</tbody>
</table>

* Unstratified analysis

O’Shaughnessy J et al. *Proc SABCS* 2010;Abstract P6-12-03.

## Safety Summary
**(n = 615 Patients with TNBC)**

<table>
<thead>
<tr>
<th>Select Grade ≥3 Adverse Events</th>
<th>Bevacizumab + chemotherapy (n = 360)</th>
<th>Chemotherapy alone (n = 255)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>7.5%</td>
<td>1.6%</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>1.7%</td>
<td>0%</td>
</tr>
<tr>
<td>GI perforation</td>
<td>0.3%</td>
<td>0.4%</td>
</tr>
<tr>
<td>ATE, VTE</td>
<td>1.7%, 3.3%</td>
<td>0.4%, 4.3%</td>
</tr>
<tr>
<td>Bleeding</td>
<td>2.2%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
<td>9.7%</td>
<td>9.4%</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>4.7%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>8.1%</td>
<td>5.1%</td>
</tr>
</tbody>
</table>

ATE = arterial thromboembolic event; VTE = venous thromboembolic event

O’Shaughnessy J et al. *Proc SABCS* 2010;Abstract P6-12-03.
Conclusions

- This meta-analysis of 621 patients with metastatic TNBC confirms the improvement in PFS previously reported in subgroup analyses from the three Phase III trials of first-line bevacizumab plus chemotherapy (RIBBON-1, E2100, AVADO).
  - Current median PFS of 8.1 months in TNBC is encouraging when compared to a typical range of 2 to 6 months with chemotherapy alone.
- No significant improvement in OS was observed.
- The safety profile of bevacizumab plus chemotherapy was consistent with previous reports.

O’Shaughnessy J et al. *Proc SABCS 2010;Abstract P6-12-03.*

Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPAQUINTO Study (GBG 44)

von Minckwitz G et al. *Proc SABCS 2010;Abstract S4-6.*
**Study Design**

**Accrual:** 1,948 (Closed)

**Eligibility**
- Untreated breast cancer
- Breast lesion $\geq 2$ cm (by palpation) or $\geq 1$ cm (by ultrasound)
- HER2-negative
- Tumor stage:
  - cT4 or cT3
  - cT2 (if HR- or cN+)
  - cT1 (if HR- or pNSLN+)
- Normal organ function

**Primary objective:** pCR rate

*Nonresponders were randomized to other treatments*

von Minckwitz G et al. *Proc SABCS 2010;Abstract S4-6.*

**Results**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>EC-Doc n = 968</th>
<th>EC-Doc+Bev n = 959</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>pCR(^1)</td>
<td>15%</td>
<td>17.5%</td>
<td>NS</td>
</tr>
<tr>
<td>pCR (other definition)(^2)</td>
<td>18.5%</td>
<td>20.3%</td>
<td>NS</td>
</tr>
<tr>
<td>pCR (other definition)(^3)</td>
<td>21.3%</td>
<td>23.9%</td>
<td>NS</td>
</tr>
<tr>
<td>Breast conservation rate</td>
<td>66.6%</td>
<td>65.8%</td>
<td>NR</td>
</tr>
</tbody>
</table>

**pCR definitions:**

\(^1\)Defined as no invasive/noninvasive residual in breast and nodes based on central pathology report review
\(^2\)No invasive residual in breast and nodes
\(^3\)No invasive residual in breast
NS, nonsignificant; NR, not reported

von Minckwitz G et al. *Proc SABCS 2010;Abstract S4-6.*
Multivariate Analysis of pCR According to Subtype*

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Odds Ratio¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>1.21</td>
</tr>
<tr>
<td>ER/PgR-negative</td>
<td>1.42</td>
</tr>
<tr>
<td>ER/PgR-positive</td>
<td>1.05</td>
</tr>
<tr>
<td>T1-3 and N0-2</td>
<td>1.17</td>
</tr>
<tr>
<td>T4 or N3</td>
<td>1.70</td>
</tr>
</tbody>
</table>

* Predefined and stratified
¹ Odds ratio >1 favors more patients with pCR on the EC-Doc + Bev arm.


Conclusions

- The addition of bevacizumab to neoadjuvant therapy for patients with early HER2-negative breast cancer does not significantly increase pCR.
- Toxicity was increased by adding bevacizumab (data not shown)
  - Serious adverse events occurred in 11.8% of EC group, 15.7% of EC-Bev group, 12.9% of Doc group and 23.1% of Doc+Bev group.
  - Events with major increases due to bevacizumab included febrile neutropenia, nausea, mucositis, general condition and wound healing.
- Multivariate analysis by breast cancer subtype suggests the addition of bevacizumab in the triple-negative population may improve pCR rate.

Investigator Commentary: First-Line Bevacizumab-Containing Therapy in Triple-Negative Metastatic BC

The ATHENA trial was an effort to get a "real world" look at various chemotherapy agents with bevacizumab as first-line therapy in routine oncology clinical practices. In this update, the investigators focused on patients with advanced triple-negative breast cancer (TNBC) and demonstrated that these patients had a less favorable time to disease progression and overall survival than do other “flavors” of breast cancer, even when treated with bevacizumab. The randomized studies suggest that bevacizumab can improve time to disease progression in TNBC, but because the overall rate of growth in TNBC is quicker, the difference in time to progression gains is smaller despite the use of bevacizumab.

In the updated meta-analysis, O’Shaughnessy and colleagues focused on outcomes in advanced TNBC and showed that adding bevacizumab to chemotherapy modestly improves the response rate from approximately 23 to 42 percent, which translates into improvements in progression-free survival of about 2.5 months but no difference in overall survival. There are potential benefits of bevacizumab in the first-line setting, but the absolute gains are modest, in part because of the rapid trajectory of progression in TNBC.

Interview with Harold J Burstein, MD, PhD, December 22, 2010

Investigator Commentary: GEPARQUINTO (GBG 44): Neoadjuvant Chemotherapy/Bevacizumab in HER2-Negative BC

GEPARQUINTO was a large study with over 1,000 HER2-negative patients. It was a complicated trial in which patients received epirubicin/cyclophosphamide (EC) with or without bevacizumab followed by docetaxel with or without bevacizumab after four cycles for responding patients.

The pathologic complete response (pCR) rate — defined as no invasive disease or noninvasive disease in the breast or lymph nodes — was not significantly different between the EC/docetaxel and the EC/docetaxel with bevacizumab arms. Even when evaluating outcome by other definitions of pCR, no differences were observed. Additionally, no difference in the rate of breast conservation was achieved with the addition of bevacizumab.

The only subset for whom there was a suggestion of benefit from bevacizumab — and this has been seen in trials of bevacizumab in the metastatic setting — was the group of patients with triple-negative breast cancer. Of course, it’s a subset analysis, so it is difficult to make any strong conclusions.

Interview with William J Gradishar, MD, January 4, 2011